연구성과로 돌아가기

2021 연구자 정보 (136 / 1146)

※ 컨트롤 + 클릭으로 열별 다중 정렬 가능합니다.
Excel 다운로드
Author Name 제1저자 여부 교신저자 여부 Address ResearcherID ORCID Paper Title WoS Edition 최상위 JCR(%) WoS Category Related Email
Gonzalez, Maria Sarai
(González, MS)
Consultorio Doctora Maria Sarai Gonzalez Huezo, Metepec, Mexico

[JCR상위 4.8] Efficacy, safety, and tolerability of seladelpar in patients with compensated liver cirrhosis due to primary biliary cholangitis (PBC): a pooled analysis of phase 2 and phase 3 studies SCIE 4.8 GASTROENTEROLOGY & HEPATOLOGY ychoi@cymabay.com;
Gordon, Stuart C.
(Gordon, SC)
제1저자 Henry Ford Hlth Syst, Detroit, MI USA

[JCR상위 4.8] Efficacy, safety, and tolerability of seladelpar in patients with compensated liver cirrhosis due to primary biliary cholangitis (PBC): a pooled analysis of phase 2 and phase 3 studies SCIE 4.8 GASTROENTEROLOGY & HEPATOLOGY ychoi@cymabay.com;
Goulis, Ioannis
(Goulis, I)
Aristotle Univ Thessaloniki, Dept Internal Med 4, Gen Hosp Thessaloniki Hippokratio, Sch Med, Thessaloniki, Greece

[JCR상위 4.8] The artificial intelligence-driven model for prediction of hepatocellular carcinoma development in chronic hepatitis B patients: Derivation and validation using 11, 111 patients from Asian and Caucasian cohorts SCIE 4.8 GASTROENTEROLOGY & HEPATOLOGY pindra@empal.com;
Gulamhusein, Aliya
(Gulamhusein, A)
Toronto Gen Hosp, Toronto, ON, Canada

[JCR상위 4.8] Efficacy, safety, and tolerability of seladelpar in patients with compensated liver cirrhosis due to primary biliary cholangitis (PBC): a pooled analysis of phase 2 and phase 3 studies SCIE 4.8 GASTROENTEROLOGY & HEPATOLOGY ychoi@cymabay.com;
Hahn, Joo-Yong
(Hahn, JY)
Sungkyunkwan Univ, Samsung Med Ctr, Heart Vasc Stroke Inst, Dept Internal Med,Sch Med,Div Cardiol, 81 Irwon Ro, Seoul 06351, South Korea AAU-7250-2020
Hahn, Joo-Yong

[JCR상위 4.8] Practical guidance for P2Y12 inhibitors in acute myocardial infarction undergoing percutaneous coronary intervention SCIE 4.8 CARDIAC & CARDIOVASCULAR SYSTEMS;PHARMACOLOGY & PHARMACY myungho@chollian.net;yasuda.satoshi.hp@ncvc.go.jp;
Harrison, Stephen
(Harrison, S)
Pinnacle Clin Res Ctr, San Antonio, TX USA
Pinnacle Clin Res, San Antonio, TX USA
GON-3283-2022
Harrison, Stephen

[JCR상위 4.8] ARO-HSD reduces hepatic HSD17B13 mRNA expression and protein levels in patients with suspected NASH
[JCR상위 4.8] Efficacy, safety, and tolerability of seladelpar in patients with compensated liver cirrhosis due to primary biliary cholangitis (PBC): a pooled analysis of phase 2 and phase 3 studies
SCIE 4.8 GASTROENTEROLOGY & HEPATOLOGY jhamilton@arrowheadpharma.com;
ychoi@cymabay.com;
Honda, Satoshi
(Honda, S)
Natl Cerebral & Cardiovasc Ctr, Dept Cardiovasc Med, 6-1 Kishibe Shimmachi, Suita, Osaka 5648565, Japan GXG-5198-2022
Honda, Satoshi
0000-0002-1393-4270
Honda, Satoshi
[JCR상위 4.8] Practical guidance for P2Y12 inhibitors in acute myocardial infarction undergoing percutaneous coronary intervention SCIE 4.8 CARDIAC & CARDIOVASCULAR SYSTEMS;PHARMACOLOGY & PHARMACY myungho@chollian.net;yasuda.satoshi.hp@ncvc.go.jp;
Huang, Jonathan
(Huang, J)
Univ Rochester, Rochester, NY 14627 USA

[JCR상위 4.8] Efficacy, safety, and tolerability of seladelpar in patients with compensated liver cirrhosis due to primary biliary cholangitis (PBC): a pooled analysis of phase 2 and phase 3 studies SCIE 4.8 GASTROENTEROLOGY & HEPATOLOGY ychoi@cymabay.com;
Hui, Aric J.
(Hui, AJ)
Alice Ho Miu Ling Nethersole Hosp, Hong Kong, Peoples R China

[JCR상위 4.8] Safety, efficacy, and pharmacodynamic (PD) activity of 12 weeks treatment with oral RIG-I agonist, inarigivir (IRIG), plus 48 weeks of tenofovir alafenamide in adult patients with chronic hepatitis B: a phase 2 collaboration study SCIE 4.8 GASTROENTEROLOGY & HEPATOLOGY jenny.yang@gilead.com;
Hwang, Jin-Yong
(Hwang, JY)
Gyeonsang Natl Univ, Gyeongsang Natl Univ Hosp, Dept Internal Med, Sch Med, 79 Gangnam Ro, Jinju 52727, South Korea
0000-0002-6632-7239
Hwang, Jin Yong
[JCR상위 4.8] Practical guidance for P2Y12 inhibitors in acute myocardial infarction undergoing percutaneous coronary intervention SCIE 4.8 CARDIAC & CARDIOVASCULAR SYSTEMS;PHARMACOLOGY & PHARMACY myungho@chollian.net;yasuda.satoshi.hp@ncvc.go.jp;
Idilman, Ramazan
(Idilman, R)
Ankara Univ, Dept Gastroenterol, Sch Med, Ankara, Turkey
Ankara Univ, Sch Med, Gastroenterol, Ankara, Turkey
AFL-0461-2022
Idilman, Ramazan

[JCR상위 4.8] The artificial intelligence-driven model for prediction of hepatocellular carcinoma development in chronic hepatitis B patients: Derivation and validation using 11, 111 patients from Asian and Caucasian cohorts
[JCR상위 5.9] IMPACT OF HBEAG ON HEPATOCELLULAR CARCINOMA RISK DURING ORAL ANTIVIRAL TREATMENT IN PATIENTS WITH CHRONIC HEPATITIS B
SCIE 4.8 GASTROENTEROLOGY & HEPATOLOGY pindra@empal.com;
Jang, Eun Sun
(Jang, ES)
Seoul Natl Univ, Dept Internal Med, Bundang Hosp, Coll Med, Seoul, South Korea

[JCR상위 4.8] The artificial intelligence-driven model for prediction of hepatocellular carcinoma development in chronic hepatitis B patients: Derivation and validation using 11, 111 patients from Asian and Caucasian cohorts SCIE 4.8 GASTROENTEROLOGY & HEPATOLOGY pindra@empal.com;
Janssen, Harry
(Janssen, H)
Univ Hlth Network, Toronto Western & Gen Hosp, Liver Clin, Toronto, ON, Canada

[JCR상위 4.8] The artificial intelligence-driven model for prediction of hepatocellular carcinoma development in chronic hepatitis B patients: Derivation and validation using 11, 111 patients from Asian and Caucasian cohorts SCIE 4.8 GASTROENTEROLOGY & HEPATOLOGY pindra@empal.com;
Jeong, Sook-Hyang
(Jeong, SH)
Seoul Natl Univ, Bundang Hosp, Seongnam Si, South Korea J-5642-2012
Jeong, Sook-Hyang

[JCR상위 4.8] Efficacy, safety, and tolerability of seladelpar in patients with compensated liver cirrhosis due to primary biliary cholangitis (PBC): a pooled analysis of phase 2 and phase 3 studies SCIE 4.8 GASTROENTEROLOGY & HEPATOLOGY ychoi@cymabay.com;
Jeong, Young-Hoon
(Jeong, YH)
Gyeongsang Natl Univ, Dept Internal Med, Changwon Hosp, 11 Samjeongja Ro, Changwon 51472, Japan F-3476-2015
Jeong, Young-Hoon

[JCR상위 4.8] Practical guidance for P2Y12 inhibitors in acute myocardial infarction undergoing percutaneous coronary intervention SCIE 4.8 CARDIAC & CARDIOVASCULAR SYSTEMS;PHARMACOLOGY & PHARMACY myungho@chollian.net;yasuda.satoshi.hp@ncvc.go.jp;
페이지 이동: